Cargando…

T-cell agonists in cancer immunotherapy

Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Yeonjoo, Shi, Yaoyao, Haymaker, Cara L, Naing, Aung, Ciliberto, Gennaro, Hajjar, Joud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537335/ https://www.ncbi.nlm.nih.gov/pubmed/33020242 http://dx.doi.org/10.1136/jitc-2020-000966

Ejemplares similares

Strategies for improving the management of immune-related adverse events
por: Naing, Aung, et al.
Publicado: (2020)

Targeting the indoleamine 2,3-dioxygenase pathway in cancer
por: Moon, Yong Wha, et al.
Publicado: (2015)

Next-Generation Immunotherapies to Improve Anticancer Immunity
por: Shi, Yaoyao, et al.
Publicado: (2021)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer
por: Marmonti, Enrica, et al.
Publicado: (2022)

Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
por: Augustin, Ryan C., et al.
Publicado: (2022)

Co-stimulatory agonists: An insight into the immunotherapy of cancer
por: Pourakbari, Ramin, et al.
Publicado: (2021)

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
por: Stephen, Bettzy, et al.
Publicado: (2023)

Emerging Cancer Vaccines: The Promise of Genetic Vectors
por: Aurisicchio, Luigi, et al.
Publicado: (2011)

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009)

Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
por: Motedayen Aval, Leila, et al.
Publicado: (2020)

Engineering Therapeutic Strategies in Cancer Immunotherapy via Exogenous Delivery of Toll-like Receptor Agonists
por: Jeong, Sehwan, et al.
Publicado: (2021)

On the connections between cancer stem cells and EMT
por: Cioce, Mario, et al.
Publicado: (2012)

The perfect personalized cancer therapy: cancer vaccines against neoantigens
por: Aurisicchio, Luigi, et al.
Publicado: (2018)

Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response
por: Valenti, Fabio, et al.
Publicado: (2021)

PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint
por: Haymaker, Cara, et al.
Publicado: (2012)

Development of OX40 agonists for canine cancer immunotherapy
por: Ruiz, Damien, et al.
Publicado: (2022)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

The emerging role of cancer cell plasticity and cell-cycle quiescence in immune escape
por: Bruschini, Sara, et al.
Publicado: (2020)

Immunotherapy in gynecological cancers
por: Lorusso, Domenica, et al.
Publicado: (2021)

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021)

The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview
por: Veneziani, Irene, et al.
Publicado: (2022)

A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain
por: Naing, Cho, et al.
Publicado: (2014)

Associations between the gut microbiome and fatigue in cancer patients
por: Hajjar, Joud, et al.
Publicado: (2021)

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023)

Tumor-targeted delivery of a STING agonist improves cancer immunotherapy
por: Wu, You-tong, et al.
Publicado: (2022)

The promise of anti-ErbB3 monoclonals as new cancer therapeutics
por: Aurisicchio, Luigi, et al.
Publicado: (2012)

Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity
por: Malu, Shruti, et al.
Publicado: (2013)

Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
por: Tapia, Coya, et al.
Publicado: (2020)

Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors
por: Rojas, Frank, et al.
Publicado: (2022)

Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma
por: Fattore, Luigi, et al.
Publicado: (2020)

Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy
por: Go, Eun-Jin, et al.
Publicado: (2020)

Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2020)

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
por: Salomon, Ran, et al.
Publicado: (2022)

Stimuli-Responsive Polymeric Nanomaterials for the Delivery of Immunotherapy Moieties: Antigens, Adjuvants and Agonists
por: Nagareddy, Raveena, et al.
Publicado: (2021)

Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists
por: Andón, Fernando Torres, et al.
Publicado: (2022)

Differential Response of Two Human Breast Cancer Cell Lines to the Phenolic Extract from Flaxseed Oil †
por: Sorice, Angela, et al.
Publicado: (2016)

Drug repurposing against COVID-19: focus on anticancer agents
por: Ciliberto, Gennaro, et al.
Publicado: (2020)

Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives
por: Huang, Cuiqing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l8hgsnojpq28scm7qaci2eb63f